Article

Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in <i>RAS</i> -mutated chronic myelomonocytic leukemia

2023-04-08

Abstract excerpt

<h4>ABSTRACT</h4> RAS pathway mutations, which are present in 30% of patients with chronic myelomonocytic leukemia (CMML) at diagnosis, confer a high risk of resistance to and progression after hypomethylating agent (HMA) therapy, the current standard of care for the disease. Using single-cell, multi-omics technologies, we sought to dissect the biological mechanisms underlying the initiation and progression of R...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 867ad115-8b64-5806-bf60-153a6722ae56
DOI: 10.1101/2023.04.07.535928

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in <i>RAS</i> -mutated chronic myelomonocytic leukemiaDOI 10.1101/2023.04.07.535928Read

Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.Semantic proximity Read

Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovationsSemantic proximity Read

Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment.Semantic proximity Read

Emerging drugs for the treatment of chronic myelomonocytic leukemia.Semantic proximity Read

Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.Semantic proximity Read

How I diagnose and treat chronic myelomonocytic leukemia.Semantic proximity Read

<i>RAS</i> mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axisSemantic proximity Read

Targeting HMGA1-driven leukemic transformation in myeloproliferative neoplasms with pacritinibSemantic proximity Read

Novel therapeutic targets for chronic myelomonocytic leukemia.Semantic proximity Read

Chronic myelomonocytic leukemia without increased classical monocyte subsets exhibits a distinct genetic profile, including frequent CBL mutations.Semantic proximity Read

Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia.Semantic proximity Read

Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms.Semantic proximity Read